Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FLU-MAL VLP

Financiado

Cerrado

Chimeric Influenza VLP used as vaccine platform for presentation of foreign anti...

Chimeric Influenza VLP used as vaccine platform for presentation of foreign antigens Application to Malaria antigens The goal of this project is to provide a new antigen delivery system for vaccination purpose. We want to develop a vaccine platform based on pseudo-viral particles (VLP), able to enhance antigen immunogenicity and allow for screen... ver más

21/12/2016

UNIVERSITE LYON 1...

194K€

Presupuesto del proyecto: 194K€

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-12-21 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITE LYON 1 CLAUDE BER...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EDUFLUVAC Combinatorial immunization strategy to educate the immune sy... 6M€ Cerrado

FLUTCORE Development of a universal influenza vaccine based on tandem... 4M€ Cerrado

Prevent-nCoV Prevention of SARS CoV 2 infection through development and c... 3M€ Cerrado

PID2020-113184RB-C21 VACUNAS PEPTIDICAS, ESTRATEGIAS ANTIVIRALES Y MECANISMOS DE... 169K€ Cerrado

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

AGL2010-22200-C02-02 CARACTERIZACION DE LA RESPUESTA INMUNE INDUCIDA POR CEPAS DE... 157K€ Cerrado

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 194K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The goal of this project is to provide a new antigen delivery system for vaccination purpose. We want to develop a vaccine platform based on pseudo-viral particles (VLP), able to enhance antigen immunogenicity and allow for screening multiple antigens independently or simultaneously. A chimeric influenza-VLP platform will be construct, where hemagglutinin (HA) protein will be modified to accommodate exogenous peptides containing B- and/or T- cell epitopes, thus allowing foreign antigen incorporation. The first objective is to select the best chimeric influenza-VLP construction to increase immunogenicity of vectorized antigens. The second objective is to provide a robust and scalable production process and a well-characterized chimeric influenza-VLP platform. The third objective is to validate our vaccination strategy by assaying its efficacy with malaria antigens to immunize against parasite infection and/or blood-stage development of the disease. The strength of this project and its high likelihood of success are based on a synergistic collaboration between three internationally recognized laboratories that would bring their complementary expertise to reach the ultimate goal of the project: delivering a new malaria vaccine-candidate. This will be supported by a complete characterization of the production process and of the final product for transfer to industrial manufacturing. The laboratory VirPath of Pr. Lina, will bring its expertise on influenza virus and vaccine production. Laboratory of Dr. Kamen NRC-Montréal developed for 2-3 years an influenza-VLP production technology based on HEK293 cells. We will transfer and exploit this know-how to select the best production process for chimeric influenza-VLPs and further optimize it. Choice of malaria target antigens and immunology tests on mouse models will be performed by the Malaria Immunology Laboratory of Dr. Rénia in Singapore, bringing its expertise and know-how of malaria immunopathology and vaccines.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores